Blood Peptidome-Degradome Profile of Breast Cancer
暂无分享,去创建一个
Ronald J. Moore | Richard D. Smith | Brianne Petritis | D. Camp | M. Gritsenko | F. Esteva | S. Purvine | Yufeng Shen | Tao Liu | R. Zhao | N. Tolić | B. Petritis
[1] J. Peterse,et al. Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.
[2] A. Olshen,et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.
[3] M. Sporn,et al. The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.
[4] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[5] M. Ferrari,et al. Clinical proteomics: Written in blood , 2003, Nature.
[6] Ronald J. Moore,et al. Making broad proteome protein measurements in 1-5 min using high-speed RPLC separations and high-accuracy mass measurements. , 2005, Analytical chemistry.
[7] Ronald J Moore,et al. Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. , 2004, Analytical chemistry.
[8] K. Honn,et al. Thrombin increases the metastatic potential of tumor cells , 1993, International journal of cancer.
[9] Ch.B. F.R.C.P. David V. Schapira M.B.,et al. Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer , 2005, Breast Cancer Research and Treatment.
[10] Steven Patierno,et al. Tissue factor, thrombin, and cancer. , 2003, Chest.
[11] R. Aebersold,et al. A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.
[12] Nikola Tolić,et al. Targeted comparative proteomics by liquid chromatography-tandem Fourier ion cyclotron resonance mass spectrometry. , 2005, Analytical chemistry.
[13] C. López-Otín,et al. Protease degradomics: A new challenge for proteomics , 2002, Nature Reviews Molecular Cell Biology.
[14] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[15] I. G. Shvyrkova,et al. Proteolytic specificity of plasmin toward adhesive proteins , 2000, Russian Journal of Bioorganic Chemistry.
[16] Wiklund Ra,et al. First of two parts , 1997 .
[17] Steven P Gygi,et al. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.
[18] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[19] M. Walport. Complement. First of two parts. , 2001, The New England journal of medicine.
[20] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[21] Timothy D. Veenstra,et al. AN ACCURATE MASS TAG STRATEGY FOR QUANTITATIVE AND HIGH THROUGHPUT PROTEOME MEASUREMENTS , 2002 .
[22] Bonnie F. Sloane,et al. Unraveling the role of proteases in cancer. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[23] E. Davie,et al. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. , 1990, The Journal of biological chemistry.
[24] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Petricoin,et al. The blood peptidome: a higher dimension of information content for cancer biomarker discovery , 2006, Nature Reviews Cancer.
[26] N. Anderson,et al. The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.
[27] D. Ankerst,et al. Afamin and Apolipoprotein A-IV: Novel Protein Markers for Ovarian Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.
[28] Piet Gros,et al. Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.
[29] X. Puente,et al. Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.
[30] H. Rus,et al. Persistent complement activation on tumor cells in breast cancer. , 1992, The American journal of pathology.
[31] F. Bost,et al. Inter-alpha-trypsin inhibitor proteoglycan family--a group of proteins binding and stabilizing the extracellular matrix. , 1998, European journal of biochemistry.
[32] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[33] J. Drews. Drug discovery: a historical perspective. , 2000, Science.
[34] John D Lambris,et al. Is complement good or bad for cancer patients? A new perspective on an old dilemma. , 2009, Trends in immunology.
[35] W. Benedict,et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.
[36] Wei Li,et al. Biochemical Characterization and Function of Complexes Formed by Hyaluronan and the Heavy Chains of Inter-α-inhibitor (HC·HA) Purified from Extracts of Human Amniotic Membrane* , 2009, The Journal of Biological Chemistry.
[37] Ronald J Moore,et al. Strategy for degradomic-peptidomic analysis of human blood plasma. , 2010, Journal of proteome research.
[38] H. Nielsen,et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. , 2008, Clinical chemistry.
[39] Yan Dong,et al. Molecular mechanism of transcriptional repression of gelsolin in human breast cancer cells. , 2002, Experimental cell research.
[40] Richard D. Smith,et al. Identification of disulfide bonds in protein proteolytic degradation products using de novo-protein unique sequence tags approach. , 2010, Journal of proteome research.
[41] Piet Gros,et al. Structure of C3b reveals conformational changes that underlie complement activity , 2006, Nature.
[42] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[43] J. Enghild,et al. The Transfer of Heavy Chains from Bikunin Proteins to Hyaluronan Requires Both TSG-6 and HC2* , 2008, Journal of Biological Chemistry.
[44] J. Potempa,et al. Alpha-2-antiplasmin: a serpin with two separate but overlapping reactive sites. , 1988, Science.
[45] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.